Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FLT3 over exp |
Gene Variant Detail | |
Relevant Treatment Approaches | FLT3 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FLT3 over exp | hepatocellular carcinoma | sensitive | FLT3 Inhibitor | Sorafenib | Clinical Study | Actionable | In an observational clinical study, hepatocellular carcinoma patients harboring FLT3 overexpression treated with Nexavar (sorafenib) demonstrated improved overall survival (24.9 months (n=67)) when compared to patients with FLT3 overexpression who received a control treatment (10.0 months (n=49)) or patients with decreased FLT3 expression treated with Nexavar (sorafenib) (16.0 months (n=71)) (PMID: 32332018). | 32332018 |
FLT3 over exp | hepatocellular carcinoma | sensitive | FLT3 Inhibitor | Sorafenib | Preclinical - Pdx | Actionable | In a preclinical study, Nexavar (sorafenib) inhibited tumor growth and reduced the percentage of tumor cells expressing Ki-67 in patient-derived xenograft (PDX) models of hepatocellular carcinoma harboring FLT3 overexpression, but had no effect on tumor growth inhibition or Ki-67 expression compared to control treatments in PDX models of HCC harboring decreased FLT3 expression (PMID: 32332018). | 32332018 |